- Home
- ORGO vs CCAP Comparison
ORGO vs CCAP Comparison
Compare ORGO & CCAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- CCAP
- Stock Information
- Founded
- ORGO 1985
- CCAP 2015
- Country
- ORGO United States
- CCAP United States
- Employees
- ORGO N/A
- CCAP N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- CCAP Finance: Consumer Services
- Sector
- ORGO Health Care
- CCAP Finance
- Exchange
- ORGO Nasdaq
- CCAP Nasdaq
- Market Cap
- ORGO 620.3M
- CCAP 562.2M
- IPO Year
- ORGO N/A
- CCAP N/A
- Fundamental
- Price
- ORGO $4.07
- CCAP $13.73
- Analyst Decision
- ORGO Buy
- CCAP Buy
- Analyst Count
- ORGO 3
- CCAP 4
- Target Price
- ORGO $7.33
- CCAP $16.38
- AVG Volume (30 Days)
- ORGO 765.7K
- CCAP 226.0K
- Earning Date
- ORGO 11-06-2025
- CCAP 11-10-2025
- Dividend Yield
- ORGO N/A
- CCAP 13.47%
- EPS Growth
- ORGO N/A
- CCAP N/A
- EPS
- ORGO N/A
- CCAP 1.19
- Revenue
- ORGO $429,531,000.00
- CCAP $183,172,000.00
- Revenue This Year
- ORGO $2.51
- CCAP N/A
- Revenue Next Year
- ORGO $25.45
- CCAP $1.43
- P/E Ratio
- ORGO N/A
- CCAP $11.56
- Revenue Growth
- ORGO N/A
- CCAP N/A
- 52 Week Low
- ORGO $2.61
- CCAP $13.31
- 52 Week High
- ORGO $6.71
- CCAP $20.19
- Technical
- Relative Strength Index (RSI)
- ORGO 40.27
- CCAP 33.73
- Support Level
- ORGO $3.84
- CCAP $13.34
- Resistance Level
- ORGO $4.40
- CCAP $14.41
- Average True Range (ATR)
- ORGO 0.22
- CCAP 0.36
- MACD
- ORGO -0.03
- CCAP -0.06
- Stochastic Oscillator
- ORGO 26.79
- CCAP 17.85
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About CCAP Crescent Capital BDC Inc. Common stock
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.